Literature DB >> 19155239

Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts?

G Malouf1, B Falissard, D Azoulay, F Callea, L D Ferrell, Z D Goodman, Y Hayashi, H-C Hsu, S G Hubscher, M Kojiro, I O Ng, A C Paterson, M Reynes, E-S Zafrani, J-F Emile.   

Abstract

AIMS: In the era of targeted therapeutics, histological typing of hepatobiliary carcinomas has major clinical implications. Little is known about the reproducibility of the pathological diagnosis of primary liver carcinomas. Therefore, this study aimed to evaluate the worldwide variation in the pathological expert diagnoses of primary liver carcinomas with fibrous stroma in patients who did not have cirrhosis.
METHODS: A single set of slides was selected from 25 tumours, and this set was reviewed independently by 12 pathologists who have worldwide expertise in liver tumours. Reproducibility of the diagnoses was evaluated by Light's kappa, and diagnoses were clustered by multidimensional scaling. Immunohistochemistry was performed after histological review.
RESULTS: The interobserver reproducibility for diagnosis of hepatocellular carcinoma subtypes and cholangiocarcinomas was poor (kappa 0.23-0.52), even when the experts considered that the diagnosis required no additional stains or clinical information. Interestingly, multidimensional scaling revealed three main clusters of tumours: hepatocellular carcinoma with no other specifications (n = 13), fibrolamellar hepatocellular carcinoma (n = 3) and cholangiocarcinoma (n = 9). Using immunohistochemistry, these histological clusters correlated with expression of anti-hepatocyte and anti-cytokeratin 19 (p<0.001).
CONCLUSIONS: The results demonstrate the poor reproducibility among experts of the pathological diagnosis of primary liver carcinomas with fibrous stroma in patients who did not have cirrhosis, and highlight that the systematic use of immunohistochemistry may improve the diagnostic accuracy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155239     DOI: 10.1136/jcp.2008.062620

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

1.  Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.

Authors:  Elana P Simon; Catherine A Freije; Benjamin A Farber; Gadi Lalazar; David G Darcy; Joshua N Honeyman; Rachel Chiaroni-Clarke; Brian D Dill; Henrik Molina; Umesh K Bhanot; Michael P La Quaglia; Brad R Rosenberg; Sanford M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-21       Impact factor: 11.205

Review 2.  Liver transplantation for cholangiocarcinoma: Current status and new insights.

Authors:  Gonzalo Sapisochín; Elena Fernández de Sevilla; Juan Echeverri; Ramón Charco
Journal:  World J Hepatol       Date:  2015-10-08

3.  Intracranial metastasis in fibrolamellar hepatocellular carcinoma.

Authors:  William J Hammond; Gadi Lalazar; James A Saltsman; Benjamin A Farber; Enrico Danzer; Tshering C Sherpa; Charles D Banda; Jeffrey R Andolina; Sasan Karimi; Cameron W Brennan; Michael S Torbenson; Michael P La Quaglia; Sanford M Simon
Journal:  Pediatr Blood Cancer       Date:  2017-12-29       Impact factor: 3.167

4.  Lung mass in a 28-year-old male: a case report of a rare tumor.

Authors:  Robert M Mroz; M Korniluk; E Swidzinska; J Dzieciol; J Czaban; B Panek; E Chyczewska
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

5.  Claudins and tricellulin in fibrolamellar hepatocellular carcinoma.

Authors:  Attila Patonai; Boglárka Erdélyi-Belle; Anna Korompay; Aron Somorácz; Beate K Straub; Peter Schirmacher; Ilona Kovalszky; Gábor Lotz; András Kiss; Zsuzsa Schaff
Journal:  Virchows Arch       Date:  2011-04-19       Impact factor: 4.064

6.  Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features.

Authors:  Gabriel G Malouf; Tomomitsu Tahara; Valérie Paradis; Monique Fabre; Catherine Guettier; Jumpei Yamazaki; Hi Long; Yue Lu; Noël J-M Raynal; Jaroslav Jelinek; Roger Mouawad; David Khayat; Laurence Brugières; Eric Raymond; Jean-Pierre J Issa
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

Review 7.  Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.

Authors:  Gadi Lalazar; Sanford M Simon
Journal:  Semin Liver Dis       Date:  2018-02-22       Impact factor: 6.115

8.  Fibrolamellar carcinomas are positive for CD68.

Authors:  Hillary M Ross; Hubert D J Daniel; Perumal Vivekanandan; Rajesh Kannangai; Matthew M Yeh; Tsung-Teh Wu; Hala R Makhlouf; Michael Torbenson
Journal:  Mod Pathol       Date:  2010-11-26       Impact factor: 7.842

9.  Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases.

Authors:  Aline Lopes Chagas; Luciana Kikuchi; Paulo Herman; Regiane S S M Alencar; Claudia M Tani; Márcio Augusto Diniz; Vincenzo Pugliese; Manoel de Souza Rocha; Luiz Augusto Carneiro D'Albuquerque; Flair Jose Carrilho; Venancio A F Alves
Journal:  Clinics (Sao Paulo)       Date:  2015-03-01       Impact factor: 2.365

Review 10.  Fibrolamellar carcinoma: 2012 update.

Authors:  Michael Torbenson
Journal:  Scientifica (Cairo)       Date:  2012-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.